SCCM Resource Library-Wrap-Up and Summary

Video Transcription

Video Summary

The transcript discusses the challenges and developments in treating intracranial hemorrhage, emphasizing the need for better data and individualized approaches. Current criticisms include limited PCC data and inconsistent trial designs. Hematoma expansion, a predictor of outcomes, indicates higher mortality and dependency risks per milliliter of expansion. Recent trials like Anexa I and RS aim to address gaps, focusing on urgent surgery and faster agent delivery. The debate continues between using Indexa and four-factor PCC for DOAC-related hemorrhage. Future steps include analyzing costs, improving outcome definitions, and tailoring treatments to individual anti-TENA levels.

Asset Caption

45-Minute Session | Pro/Con Debate: Flip It and Reverse It: ICH Management

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

intracranial hemorrhage

hematoma expansion

PCC data

individualized treatment

DOAC-related hemorrhage

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.